Avoro Capital Advisors LLC
CIK: 0001633313Latest portfolio: $10.2B · Q4 2025
Holdings
33
Total Value
$10.2B
New Positions
11
Closed Positions
8
Top Holdings
View All 33 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | UTHUNITED THERAPEUTICS CORP | 2,606,060 | $1.3B | 12.48% | NEW | |
| 2 | ASNDASCENDIS PHARMA | 5,161,111 | $1.1B | 10.72% | NEW | Call |
| 3 | MDGLMADRIGAL PHARMACEUTICALS INC | 1,807,500 | $1.1B | 10.35% | -25,500 | |
| 4 | ARGXARGENX SE | 990,000 | $832.5M | 8.18% | — | |
| 5 | KRYSKRYSTAL BIOTECH INC | 2,888,888 | $712.2M | 7.00% | +111K | |
| 6 | ARWRARROWHEAD PHARMACEUTICALS INC | 10,625,000 | $705.4M | 6.93% | -275,000 | |
| 7 | KYMRKYMERA THERAPEUTICS INC | 7,474,747 | $581.6M | 5.72% | +1.1M | |
| 8 | GPCRSTRUCTURE THERAPEUTICS INC | 6,555,555 | $455.9M | 4.48% | NEW | |
| 9 | RNAAVIDITY BIOSCIENCES INC | 5,455,000 | $393.5M | 3.87% | -2,190,000 | |
| 10 | CNTACENTESSA PHARMACEUTICALS PLC | 14,555,555 | $364.0M | 3.58% | +3.7M | |
| 11 | CELCCELCUITY INC | 3,111,111 | $310.3M | 3.05% | NEW | |
| 12 | APLSAPELLIS PHARMACEUTICALS INC | 12,222,222 | $307.0M | 3.02% | — | |
| 13 | VERAVERA THERAPEUTICS INC | 5,888,888 | $298.2M | 2.93% | -321,112 | |
| 14 | XBISPDR SERIES TRUST - S&P BIOTECH | 2,100,000 | $256.1M | 2.52% | NEW | |
| 15 | XENEXENON PHARMACEUTICALS INC | 5,424,444 | $243.1M | 2.39% | +24K | |
| 16 | TERNTERNS PHARMACEUTICALS INC | 4,350,000 | $175.7M | 1.73% | NEW | |
| 17 | RVMDREVOLUTION MEDICINES INC | 2,170,000 | $172.8M | 1.70% | NEW | |
| 18 | QUREUNIQURE NV | 6,150,000 | $147.2M | 1.45% | +1.7M | |
| 19 | SLNOSOLENO THERAPEUTICS INC | 2,900,000 | $134.3M | 1.32% | +322K | |
| 20 | OCULOCULAR THERAPEUTIX INC | 10,777,777 | $130.8M | 1.29% | +528K | |
| 21 | TSHATAYSHA GENE THERAPIES INC | 21,700,000 | $119.3M | 1.17% | — | |
| 22 | BRD1EURMIND MEDICINE (MINDMED) INC | 5,000,000 | $67.0M | 0.66% | NEW | |
| 23 | PTCT 1.5 09/15/26PTC THERAPEUTICS INC | 685,000 | $52.0M | 0.51% | NEW | |
| 24 | VRDNVIRIDIAN THERAPEUTICS INC | 1,500,000 | $46.7M | 0.46% | NEW | |
| 25 | ORKAORUKA THERAPEUTICS INC | 1,333,340 | $40.4M | 0.40% | — |
Quarterly Changes
New Positions
Sector Breakdown
Healthcare0.0% ($1.0905181052579833e+155T)
Unknown0.0% ($12698026.7T)
Financial Services0.0% ($256.1M)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $10.2B | 34 |
| Q3 2025 | Nov 14, 2025 | $7.7T | 32 |
| Q2 2025 | Aug 14, 2025 | $5.7T | 30 |
| Q1 2025 | May 15, 2025 | $6.4T | 33 |
| Q4 2024 | Feb 14, 2025 | $7.1T | 39 |
| Q3 2024 | Nov 14, 2024 | $6858.2T | 36 |
| Q2 2024 | Aug 14, 2024 | $7508.4T | 41 |
| Q1 2024 | May 15, 2024 | $8573.5T | 46 |
| Q4 2023 | Feb 14, 2024 | $7239.8T | 42 |
| Q3 2023 | Nov 14, 2023 | $6411.2T | 46 |
| Q2 2023 | Aug 14, 2023 | $7371.2T | 43 |
| Q1 2023 | May 15, 2023 | $6745.2T | 41 |
| Q4 2022 | Feb 14, 2023 | $6691.5T | 36 |
| Q3 2022 | Nov 14, 2022 | $5.4T | 39 |
| Q2 2022 | Aug 15, 2022 | $5.1T | 40 |
| Q1 2022 | May 16, 2022 | $5.5T | 43 |
| Q4 2021 | Feb 14, 2022 | $5.9T | 41 |
| Q3 2021 | Nov 15, 2021 | $6.4T | 52 |
| Q2 2021 | Aug 16, 2021 | $5.7T | 46 |
| Q1 2021 | May 17, 2021 | $5.8T | 46 |
| Q4 2020 | Feb 16, 2021 | $5.8T | 44 |
| Q3 2020 | Nov 16, 2020 | $7.0T | 46 |
| Q2 2020 | Aug 14, 2020 | $5.1T | 45 |
| Q1 2020 | May 15, 2020 | $3.0T | 43 |
| Q4 2019 | Feb 14, 2020 | $3.4T | 32 |
| Q3 2019 | Nov 14, 2019 | $2.4T | 33 |
| Q2 2019 | Aug 14, 2019 | $2.9T | 35 |
| Q1 2019 | May 15, 2019 | $2.3T | 32 |
| Q4 2018 | Feb 14, 2019 | $1.7T | 35 |
| Q3 2018 | Nov 14, 2018 | $2.2T | 46 |
| Q2 2018 | Aug 14, 2018 | $2.6T | 44 |
| Q1 2018 | May 15, 2018 | $2.1T | 58 |
| Q4 2017 | Feb 14, 2018 | $1.5T | 52 |
| Q3 2017 | Nov 14, 2017 | $1.3T | 45 |
| Q2 2017 | Aug 14, 2017 | $792.0B | 47 |
| Q1 2017 | May 15, 2017 | $782.8B | 47 |
| Q4 2016 | Feb 14, 2017 | $495.0B | 44 |
| Q3 2016 | Nov 14, 2016 | $569.9B | 48 |
| Q2 2016 | Aug 15, 2016 | $450.0B | 48 |
| Q1 2016 | May 16, 2016 | $286.7B | 41 |
Fund Information
Avoro Capital Advisors LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $10.2B across 33 holdings. The largest position is UNITED THERAPEUTICS CORP (UTH), representing 12.5% of the portfolio. Compared to the previous quarter, the fund opened 14 new positions and closed 11 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.